During follow-up (37, 20–51 months), GPC-3 levels did not predict the development of de novo HCC in cohort A. However, in cohort B, GPC-3 > 150 pg/mL was independently associated with reduced survival (adjusted HR = 1.68, 95% CI 1.03–2.67, p = 0.036). Here, GPC3 is linked to hepatocellular carcinoma.